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Summary
Purpose: To evaluate the efﬁcacy, tolerability, and effects on behavior and psychosocial func-
tioning of lamotrigine monotherapy in children with newly diagnosed typical absence seizures.
Patients and methods: Children meeting enrollment criteria (n = 54) received a conﬁrmatory
24-h ambulatory electroencephalogram (EEG) and then entered a Escalation Phase of up to
20-weeks during which lamotrigine was titrated until seizures were controlled or maximum
dose (10.2mg/kg) was reached. Seizure freedom was assessed by diary review and clinic hyper-
ventilation (clinic HV) and then conﬁrmed by EEG with hyperventilation (HV/EEG). Patients
who maintained seizure freedom for two consecutive weekly visits were entered into the
Maintenance Phase (n = 30). Diary, clinic HV, and HV/EEG data were supplemented with 24-
h ambulatory EEG at baseline and the ends of the Escalation and Maintenance Phases. Health
outcome assessments were completed at screening and at the end of the Maintenance Phase.
Results: By the end of the Escalation Phase, seizure-free rates (responders) were 59% by seizure
diary (n = 51), 56% by HV/EEG (n = 54) (primary endpoint), and 49% by 24-h ambulatory EEG
(n = 49). During the Maintenance Phase, 89% (week 24) and 86% (week 32) remained seizure free
by diary (n = 28), 78% by clinic HV (n = 27), and 81% by 24-h ambulatory EEG (n = 26). Seizure
freedom was ﬁrst observed beginning at the ﬁfth week of the Escalation Phase. The most fre-
quent adverse events were headache and cough. Health outcome scores were either improved
or unchanged at the end of the Maintenance Phase.
 This trial is registered on clinicaltrials.gov as number NCT00144872.
∗ Corresponding author at: Dartmouth-Hitchcock Medical Center, Section of Neurology, One Medical Center Drive, Lebanon, NH 03756,
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Conclusions: Lamotrigine monotherapy results in complete seizure freedom in a substantial
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complete (10.2mg/(kg day) maximum dose). At each clinic visit,
seizure status was assessed by hyperventilation testing (two 5-min
trials) for clinical signs (clinic HV) and, if the results were eithernumber of children with typi
Introduction
Typical absence seizures, which account for approxi-
mately 10% of seizures in children, are characterized
by brief (<30 s), sudden, and unpredictable episodes of
impairment of consciousness (absence) associated with
generalized spike/polyspike-and-slow-wave discharges on
electroencephalogram (EEG) and often accompanied by
motor automatisms (Panayiotopoulos, 2001; Posner, 2005).
Patients with absence epilepsy routinely experience multi-
ple seizures per day, sometimes numbering in the hundreds
(Pearl and Holmes, 2001). Typical absence seizures occur
spontaneously or can be provoked by various triggers
such as photic stimuli or hyperventilation. Usually, onset
of typical absence seizures occurs in childhood or ado-
lescence, and seizures remit with age in many patients
(Adams and Lueders, 1981; Wirrell et al., 1996a,b; Pearl
and Holmes, 2001; Wirrell, 2003; Grosso et al., 2005;
Tovia et al., 2006). Given that frequent, often sub-
tle seizures can cause difﬁculty with accurate seizure
counts and assessment, hyperventilation during EEG mon-
itoring is an important tool in the diagnosis of typical
absence seizures (Browne et al., 1983; Wirrell et al.,
1997).
Effective control of typical absence seizures is impor-
tant given their potential impact on children’s safety as
well as behavior, cognition, and psychosocial function during
a critical period of development. Typical absence seizures
may affect children’s safety by increasing risk of acciden-
tal injury. In a study of children and adolescents <18 years
old diagnosed with either typical absence epilepsy or juve-
nile rheumatoid arthritis (a control group deﬁned by having
a non-neurological chronic disease), the risk of accidental
injury, particularly mild head injuries and injuries from bicy-
cle accidents or car accidents, was signiﬁcantly higher in
patients with typical absence epilepsy than patients with
juvenile rheumatoid arthritis (Posner, 2005; Posner et al.,
2005a).
A 2005 Cochrane review of clinical trials of ethosuximide,
valproate, and lamotrigine in typical absence seizures in
children identiﬁed only ﬁve small, randomized, prospective
studies (Posner et al., 2005b). Thus, while lamotrigine, val-
proate, and ethosuximide are each regarded as effective
for typical absence seizures, little information from clini-
cal trials is available to inform their use for typical absence
seizures in clinical practice.
The study reported herein was designed as an evaluation
of the efﬁcacy of lamotrigine monotherapy for the treat-
ment of typical absence seizures in children. This study
design was open-label with a step-wise escalation of lam-
otrigine, using the Food and Drug Administration (FDA)
guideline for rate of escalation. Our goals were to learn how
many children would become seizure free on lamotrigine
monotherapy, the dose at which lamotrigine was efﬁca-
cious, and whether there were EEG or behavior predictors
of response to lamotrigine.
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ethods
atients
ale or female patients <13 years old who were newly diag-
osed with absence epilepsy and had not previously been treated
ith antiepileptic drugs were eligible for the study. Presence of
ypical absence seizures was suspected on the basis of hyper-
entilation in the clinic and conﬁrmed by observance of clinical
nd electroencephalographic features (i.e., 2.5—4.5Hz generalized
pike-and-wave activity or multiple spike-and-wave activity last-
ng ≥3 s while awake) of typical absence seizures on a 1-h EEG
ith hyperventilation with two 5-min trials (HV/EEG). All the chil-
ren met the requirements of childhood absence epilepsy (Pearl
nd Holmes, 2008). The deﬁnition of a seizure as an electroen-
ephalographic discharge of 3 s or longer was arbitrary. However,
ost children with electrographic discharges lasting this long will
ave altered responsiveness (Porter et al., 1973; Browne et al.,
974; Pearl and Holmes, 2001). All screening HV/EEGs were also
ead centrally by an electroencephalographer (GLH) to conﬁrm the
iagnosis.
Exclusion criteria included seizures resulting from an identiﬁ-
ble intracerebral lesion; the presence of partial or generalized
onic—clonic seizures, a progressive neurological disorder; clinically
igniﬁcant chronic hepatic, renal, or cardiac conditions; a psychi-
tric disorder requiring medication; a history of a severe psychiatric
isorder requiring hospitalization; current use of psychoactive drugs
o treat attention-deﬁcit hyperactivity disorder; and pregnancy,
reastfeeding, or inability to conﬁrm sexual abstinence.
rocedures and assessments
he protocol for this open-label study was approved by institutional
eview boards for the 19 investigational sites in the United States.
ll children and/or their parents or caregivers provided written
nformed consent.
The study consisted of a 1-week Screening Phase, a 24-h Base-
ine Phase, a 20-week Escalation Phase, and a 12-week Maintenance
hase. During the Screening and Baseline Phases, patients were
valuated to determine whether they met enrollment criteria. Dur-
ng the Escalation Phase, clinic visits occurred on the second and
ourth weeks of treatment and weekly thereafter. Patients who
et enrollment criteria received The study consisted of a Screen-
ng Phase of up to 1 week, a 24-h Baseline Phase, an Escalation
hase of up to 20 weeks, and a 12-week Maintenance Phase. Dur-
ng the Screening and Baseline Phases, patients were evaluated to
etermine whether they met enrollment criteria. Ambulatory EEG
ecording was carried out during the 24-h Baseline Phase. During
he Escalation Phase, clinic visits occurred on the second and fourth
eeks of treatment and weekly thereafter. Patients who met enroll-
ent criteria received lamotrigine monotherapy titrated according
o the schedule in Table 1 (starting dose: 0.3mg/(kg day)) until the
atients became seizure free or the 20-week Escalation Phase was
Open access under CC BY license.quivocal or negative, an EEG with hyperventilation was performed.
reedom from seizures was deﬁned as no absence seizure discharges
uring the EEG with hyperventilation on two consecutive weeks.
etween visits, a single dose increment of 0.6mg/kg occurred. A
4-h ambulatory EEG followed the second seizure-free HV/EEG.
126
Table 1 Dose-escalation schedule for lamotrigine
Treatment week Dose (mg/(kg day))a
1—2 0.3b
3—4 0.6
5 1.2
6 1.8
7 2.4
8 3.0
9 3.6
10 4.2
11 4.8
12 5.4
13 6.0
14 6.6
15 7.2
16 7.8
17 8.4
18 9.0
19 9.6
20 10.2
a Patients entered the Maintenance Phase upon reaching their
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cefﬁcacious dose as determined by conﬁrmed seizure freedom at
two consecutive visits.
b This dose was given in one dose or two divided doses.
Patients who did not become seizure free during the Escalation
hase were discontinued from the study. At the end of the Escalation
hase, all patients underwent a 24-h ambulatory EEG recording prior
o entering the Maintenance Phase (patients whose seizures were
ontrolled) or discontinuing from the study (patients whose seizures
ere not controlled).
Only patients who met the criterion for seizure freedom
ntered the Maintenance Phase, during which they remained
or an additional 12 weeks at the effective dose established
uring the Escalation Phase unless dose adjustment (maximum:
5.0mg/(kg day); minimum: 0.3mg/(kg day)) was required to opti-
ize efﬁcacy or tolerability. Clinic visits occurred every 4 weeks
uring the Maintenance Phase. Clinic HV was performed at visits in
he Maintenance Phase.
At the end of the Maintenance Phase, a third 24-h ambu-
atory EEG was performed. In addition, investigators rated the
atient’s status relative to status at Screening on seven indices
Seizure Frequency, Seizure Duration, Seizure Intensity, Adverse
xperiences, Social Functioning, Intellectual Functioning, and Motor
unctioning), each scored on a 7-point scale: marked deteriora-
ion, moderate deterioration, mild deterioration, no change, mild
mprovement, moderate improvement, marked improvement. Par-
nts/caregivers also used this 7-point scale to assess the child’s
verall status at the end of the Maintenance Phase.
Health outcomes assessments completed at Screening and at
he end of the Maintenance Phase included the Child Behav-
or Checklist for Ages 6—18 (CBCL) (Shaffer et al., 1983; Harter,
985; Bird et al., 1987; Granleese and Joseph, 1994), the Chil-
ren’s Global Assessment (C-GAS)(Achenbach, 1991), and the
elf-Perception Proﬁle for Children (SPPC) (Bird et al., 1987).
he CBCL is a numeric scale (1—100) used by mental health
linicians and doctors to rate the general functioning of chil-
ren under the age of 18. The checklist captures information
n competencies and behavioral/emotional problems in the
omains of Anxious/Depressed, Withdrawn/Depressed, Somatic
omplaints, Social Problems, Thought Problems, Attention Prob-
ems, Rule-Breaking Behavior, and Aggressive Behavior (Harter,
999). Parents/caregivers were asked to rate their children’s sta-
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us over the past 6 months on each domain on a 3-point scale:
= not true; 1 = somewhat or sometimes true; 2 = very true or often
rue. The CBCL was summarized as a total score and as scores for
ach of the subscales. Total scores range from 0 to 224. Higher
cores reﬂect lower competencies and greater emotional/social
roblems. The C-GAS is a single-item assessment of overall gen-
ral functioning for children ages 4 and older (Bird et al., 1987).
arents/caregivers were asked to identify the category that best
epresents their children’s current functioning and then to specify a
alue on a 100-point scale that best corresponded to that level. The
-GAS yields a single score ranging from 0 to 100 where higher scores
eﬂect better functioning. The SPPC is an interviewer-administered
uestionnaire to assess perception of competence and adequacy
cross the domains of athletic competence, behavioral conduct,
lobal self-worth, physical appearance, scholastic competence, and
ocial acceptance (Harter, 1999). The SPPC was summarized as one
core for each domain for a total of six scores, each ranging from 1
o 4. Higher scores reﬂect better competence or self-perception.
Throughout the study, all patients and their parents/caregivers
ept seizure diaries for recording presence or absence of seizures
ach day. Adverse events, deﬁned as any untoward medical occur-
ences reported by patients or their parents/caregivers or noted
y investigators, were also recorded throughout the study. Adverse
vents were reported regardless of their cause. For each adverse
vent, investigators recorded whether or not they considered it to
e caused by study medication and whether or not it was serious.
serious adverse event was deﬁned as any untoward experience,
egardless of its suspected cause, that was fatal, life-threatening,
r permanently disabling; or that required inpatient hospitalization.
Serum samples to measure lamotrigine concentrations were col-
ected at the time of conﬁrmation of seizure freedom or at the time
f premature withdrawal from the study.
For patients discontinuing the study for any reason, lamotrigine
ose was reduced by approximately 50% per week over at least 2
eeks unless safety concerns dictated a more rapid withdrawal of
tudy medication. The use of psychoactive drugs to treat hyperac-
ivity disorder or attention-deﬁcit disorder or antiepileptic drugs
ther than study medication was prohibited throughout the study.
ata analysis
fﬁcacy data were analysed for subjects contributing data in each
hase. All available data up to the time of study discontinuation
ere included in analyses of efﬁcacy data for patients who withdrew
rom the study prematurely. Missing data were not interpolated.
The primary efﬁcacy endpoint was the proportion of patients
ith no typical absence seizures for two consecutive weeks as con-
rmed by HV/EEG during the Escalation Phase. An absence seizure
as deﬁned as a spike-and-wave or polyspike-and-wave discharge
asting ≥3 s during the awake state. This arbitrary deﬁnition was
ased on studies showing that generalized discharges of this dura-
ion are associated with impaired function (Porter et al., 1973;
rowne et al., 1974; Penry et al., 1975). A patient was considered
eizure-free at a given week if conﬁrmed seizure-free the following
eek.
Other efﬁcacy endpoints, calculated separately for the Escala-
ion and Maintenance Phases, included the percentage of patients
eizure free on 24-h ambulatory EEG; the mean number of seizures
er 24 h by 24-h ambulatory EEG; the percentages of patients with
25%, ≥50%, ≥75%, and ≥100% reductions versus Baseline in seizure
requency and seizure duration by 24-h ambulatory EEG; the per-
entages of patients with ≥25%, ≥50%, ≥75%, and ≥100% reductions
ersus Baseline in clinical signs of absence seizures on hyperventi-
ation; the mean percent change versus Baseline in days per week
ith seizures by seizure diary; and the percentage of patients
eizure free according to diary data. For the seizure diary data,
aseline values for days per week with seizures were based on
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Table 2 Demographics and patient disposition
n = 54
Demographics
Mean age, years (range) 7.3 (3—13)
Sex, n (%)
Female 34 (63)
Male 20 (37)
Race, n (%)
African American/African heritage 15 (28)
American Indian or Alaska native 4 (7)
Japanese 1 (2)
White—–Arabic/North African heritage 1 (2)
White—–White/Caucasian/European heritage33 (61)
Patient disposition
Completed the study, n (%) 28 (52)
Prematurely withdrew from the study, n (%) 26 (48)
Escalation Phase, n 24
Lack of efﬁcacya 21
Adverse event 2
Lost to follow-up 1
Patient’s decision 0
Maintenance Phase, n 2
Lack of efﬁcacy 0
Adverse event 1
Lost to follow-up 0
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the number of days with seizures during the 4 weeks preceding
study entry. Other endpoints included the percentages of patients
scored as moderately or markedly improved on the investigator
and parent/caregiver ratings of patients’ status; mean changes
from Baseline to the end of the study (deﬁned as the last visit on
study medication) on health outcomes measures; the percentage
of patients with adverse events; and serum lamotrigine concentra-
tion at the end of the Escalation Phase in the sample as a whole,
seizure-free patients (responders), and patients not seizure free
(non-responders).
For the percentages of patients seizure free by HV/EEG (primary
endpoint) and by 24-h ambulatory EEG, exact binomial two-tailed
tests for a single proportion were used to compare seizure-free rates
in this lamotrigine-treated sample with a null-hypothesis value of
20%, which represented a historical seizure-free rate in a placebo
group. The historical placebo response rate of 20% was based on
the observed seizure-free rate in the placebo group during the
4-week Maintenance Phase of the previously reported controlled
clinical trial of lamotrigine for typical absence seizures in children
(Frank et al., 1999). This seizure-free rate may overestimate the
true placebo rate because it was obtained while patients who had
been successfully treated with lamotrigine were slowly tapered off
lamotrigine to placebo. Based on published ﬁndings on the natural
history of absence epilepsy, a seizure-free rate of 20% within the
time frame of the current study would constitute a very high remis-
sion rate for untreated patients following recent diagnosis (Ferrie
et al., 1995; Buoni et al., 1999; Coppola et al., 2004a,b). Paired
two-tailed t-tests were used to compare Escalation-Phase values
and Maintenance-Phase values with Baseline values for mean per-
cent change in weekly seizure frequency by seizure diary and mean
changes in scores on the health outcomes measures. All other data
were summarized with descriptive statistics only.
According to power calculations using an estimated 50% seizure-
free rate with lamotrigine and a signiﬁcance level of 0.05, a total
of 35 evaluable patients provided at least 90% power to detect a
signiﬁcant difference between lamotrigine and a historical placebo
group with a seizure-free rate of 20% for the primary endpoint.
Because a 30% dropout rate was assumed, planned enrollment was
approximately 50 patients in order to obtain 35 evaluable patients.
Results
Patients
The number of patients enrolled in the study was 54, all of
whom took at least one dose of study medication and were
therefore included in the Intent-to-Treat Population. Two
thirds of the sample was female, and the mean age of the
patients was 7.3 years (range 3—13) (Table 2).
Of the 54 patients enrolled in the study, 28 (52%) com-
pleted the study and 26 (48%) prematurely withdrew. The
primary reason for premature withdrawal was lack of efﬁ-
cacy (Table 2). All withdrawals for lack of efﬁcacy (i.e., 21
of the total 26 premature withdrawals in the study) occurred
at the end of the Escalation Phase because patients met the
exit criterion of not being seizure free at the end of that
phase.
Seizure statusHV/EEG
At the end of the Escalation Phase, thirty patients were
seizure free by HV/EEG (primary endpoint) (30/54, 56%,
p < 0.0001 versus a historical 20% incidence of seizure free-
C
A
h
mPatient’s decision 1
a These patients met the exit criterion of not being seizure
free at the end of the Escalation Phase.
om with placebo). Seizure freedom occurred in some
atients beginning on the ﬁfth week of the Escalation Phase.
4-h Ambulatory EEG
f the 49 patients with evaluable ambulatory EEG data at
he end of the Escalation Phase, 24 (49%) were seizure free
p < 0.0001 versus historical 20% placebo rate). Of the 26
atients with evaluable ambulatory EEG data at the end
f the Maintenance Phase, which consisted only of patients
ho achieved seizure freedom during the Escalation Phase,
1 (81%) were seizure free (p≤ 0.001 versus historical 20%
lacebo rate). Of the 54 patients entered into the study, 21
39%) reached the Maintenance Phase and remained seizure
ree. The mean± S.D. number of absence seizures per 24 h
as 25.6± 44.5 at the end of the Escalation Phase and
.3± 16.8 at the end of the Maintenance Phase compared
ith 60.4± 49.9 at Baseline. During both the Escalation
hase and the Maintenance Phase, the majority of patients
ad at least a 75% reduction in seizure frequency and seizure
uration on 24-h ambulatory EEG. Table 3 lists the percent-
ge of patients with reduction in spike-wave discharges by
5%, 50%, 75%, and 100% in patients during the escalation
nd Maintenance Phases.linic HV
t Baseline, additional clinical signs of absence seizures on
yperventilation included staring (80% of patients), impair-
ent of consciousness (69%), eye blinking (50%), eye rolling
128 G.L. Holmes et al.
Table 3 Percent of patients with ≥25%, ≥50%, ≥75%, and 100% reduction in seizure frequency and duration on 24-h ambulatory
EEG or Clinic HV at the end of escalation and maintenance, which consisted only of patients who achieved seizure freedom during
the Escalation Phase
Seizure frequency on 24-h
ambulatory EEG
Seizure duration on 24-h
ambulatory EEG
Clinic HV
Escalation Phase n = 46 n = 46 n = 53
≥25% reduction 76 76 55
≥50% reduction 72 74 26
≥75% reduction 59 61 4
100% reduction 48 48 0
Maintenance Phase n = 26 n = 26 n = 27
≥25% reduction 88 92 100
≥50% reduction 81 92 93
≥75% reduction 81 81 85
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46%), chewing movements (20%), hand movements (15%),
nd other automatisms (7%). During the Escalation Phase, 29
f 53 patients had at least a 25% reduction in clinical signs of
bsence seizures (Table 3). During the Maintenance Phase,
hich consisted only of patients who achieved seizure free-
om during the Escalation Phase, all 27 patients had at least
25% reduction in clinical signs of absence seizures, and 6
f 27 patients had a 100% reduction (Table 3).
eizure diary data
he mean± S.D. percent change versus Baseline in days per
eek with seizures by seizure diary was −25.2%± 171.39
p = 0.2979 versus Baseline) during the Escalation Phase
nd −95.5%± 13.85 during the Maintenance Phase
p < 0.0001 versus Baseline). By seizure diary, approxi-
ately half 23 of 51 patients were seizure free by week 14
f treatment, and 25 of 28 (week 24) and 24 of 28 (week
2) patients were seizure free during the Maintenance
hase.
haracteristics of responders and non-responders
o lamotrigine
o determine if there were factors that predicted response
o lamotrigine, we evaluated clinical and electroencephalo-
raphic features in lamotrigine responders (no seizures)
nd non-responders. There were no differences in mean
ge (responders 7.2± 2.6 years; non-responders 7.5± 2.9
ears), baseline number of days per week with seizures
responders 6.0± 2.1; non-responders 6.1± 2.3), baseline
eizure number on the pre-drug 24 h EEG (responders
7.8± 49.3 seizures; non-responders 63.7± 51.4 seizures),
aseline total seizure duration on the pre-drug 24 h EEG
responders 532.5± 436 s; non-responders 662.8± 467.8 s)
nd baseline total duration of absence seizures (respon-
ers 617.45± 426.75 s; non-responders 594.00± 454.59 s,
> 0.05). There were also no differences in responder rate
etween young children (3—7 years; 14 of 28 patients
esponsed) and older children (8—13 years; 16 of 26 patients
esponsed).
A
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w81 78
nvestigator and parent/caregiver ratings of
atient’s status
n the investigator rating of clinical status, the percentage
f patients scored as showing moderate or marked improve-
ent from the beginning of the study to the end of the
aintenance Phase was 97% for Overall Status, 100% for
eizure Frequency, 97% for Seizure Duration, 96% for Seizure
ntensity, 28% for Adverse Experiences, 37% for Social Func-
ioning, 41% for Intellectual Functioning, and 27% for Motor
unctioning (Table 4). On the parent/caregiver assessment
f overall status, 100% of patients were rated as showing
oderate or marked improvement from the beginning of the
tudy to the end of the Maintenance Phase.
ealth outcomes
he mean± S.D. change from Baseline to the end of the
tudy in CBCL total score reﬂected a signiﬁcant improve-
ent in behavior (−10.8± 17.3; p = 0.0009). Mean± S.D.
hanges from Baseline also reﬂected signiﬁcant improve-
ent in the domains of Anxious/Depressed (−1.2± 2.5,
= 0.010), Aggressive Behavior (−1.7± 3.1, p = 0.003),
ocial Problems (−1.7± 2.3, p < 0.001), Thought Problems
−1.6± 2.9, p = 0.003), and Attention Problems (−2.2± 5.0,
= 0.017). Mean changes from Baseline did not reﬂect
tatistically signiﬁcant improvement in the domains of With-
rawn/Depressed, Somatic Complaints, or Rule-Breaking
ehavior.
Mean± S.D. C-GAS scores did not signiﬁcantly differ
between Baseline (86.7± 9.5, reﬂecting good functioning)
and the end of the study (89.0± 8.0). Likewise, mean
changes from Baseline to the end of the study in SPPC
subscale scores were not statistically signiﬁcant except for
social acceptance (2.1, p = 0.046).dverse events
he most common adverse events reported during the study
ere headache and cough (Table 5). Rash was reported in
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Table 4 Investigators’ global assessment at the end of the Maintenance Phase
Deterioration No change Improvement
Marked Moderate Mild Mild Moderate Marked
Overall status 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 6 (21) 22 (76)
Seizure frequency 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (7) 27 (93)
Seizure duration 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 27 (93)
Seizure intensity 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 27 (93)
Adverse experiences 0 (0) 0 (0) 3 (10) 18 (62) 0 (0) 0 (0) 8 (28)
Social functioning 0 (0) 0 (0) 1 (3) 14 (48) 3 (10) 1 (3) 10 (34)
Intellectual functioning 0 (0) 0 (0) 1 (3) 13 (45) 3 (10) 3 (10) 9 (31)
Motor functioning 0 (0) 0 (0) 1 (3)
Data are expressed as n (% patients); n = 29.
six patients (11%) subjects, urticaria in one patient (2%),
and pruritus in two patients (4%). None of the incidents
of rash were considered to be drug related; the urticaria
and pruritus were considered possibly to be drug related.
None of these events was serious or resulted in premature
withdrawal from the study.
Three patients had adverse events that led to prema-
ture withdrawal from the study: increased seizure activity
in one patient, tremor in one patient, and vomiting and
dizziness in one patient. In the investigators’ judgment, all
of these adverse events were possibly caused by lamotrig-
ine. One of the adverse events, increased absence seizure
activity in a 4-year-old male patient, was considered to
be serious. This event was observed beginning 16 weeks
after initiation of lamotrigine and 2 days after dose adjust-
ment to 8.74mg/(kg day). The patient was hospitalized for
evaluation while lamotrigine was discontinued and ethosux-
imide was initiated. The event resolved by 3 days after its
onset.
Table 5 Number (%) of patients with adverse events
Number (%) patients, n = 54
Headache 20 37)
Cough 12 22)
Upper abdominal pain 10 19)
Nasal congestion 10 19)
Nasopharyngitis 8 15)
Pyrexia 7 13)
Rash 6 11)
Viral gastroenteritis 5 9)
Dizziness 5 9)
Psychomotor hyperactivity 5 9)
Nausea 4 7)
Pain in extremity 4 7)
Pharyngolaryngeal pain 3 6)
Constipation 3 6)
Stomach discomfort 3 6)
Vomiting 3 6)
Streptococcal pharyngitis 3 6)
Sinusitis 3 6)
Adverse events reported in ≥5% of patients are listed.
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amotrigine serum concentrations
mong the 29 patients with available data on lamotrigine
erum concentrations, mean± S.D. (range) trough serum
oncentration at the end of the Escalation Phase was
.4± 4.3g/mL (2.9—20.8). At the end of the Escalation
hase, 19 of the 29 patients with lamotrigine serum-
oncentration data were seizure free, and the remaining 10
atients were not seizure free. Mean± S.D. (range) trough
erum concentration at the end of the Escalation Phase
as 6.3± 2.2g/mL (2.9—10.4) among the 19 seizure-free
atients and 12.5± 4.5g/mL (3.5—20.8) among the 10
atients who were not seizure free.
iscussion
his EEG-based study supports a role for lamotrigine in the
reatment of typical absence seizures in children and adoles-
ents. Complete seizure control by HV/EEG occurred in some
amotrigine-treated patients beginning on the ﬁfth week of
he Escalation Phase. By the end of the Escalation Phase,
eizure-free rates were 59% by seizure diary, 56% by HV/EEG,
nd 49% by 24-h ambulatory EEG. Seizure control was largely
aintained during the 12-week Maintenance Phase, during
hich the percentage of patients who remained seizure free
as 89% (week 24) and 86% (week 32) by seizure diary, 78% by
linic HV, and 81% by 24-h ambulatory EEG. Lamotrigine was
lso associated with improvement in patients’ clinical sta-
us and behavioral functioning as rated by both investigators
nd parents/caregivers and as assessed on the CBCL.
Mean trough serum concentration at the effective dose of
amotrigine among patients seizure free was 6.3g/mL. The
nding that lamotrigine serum concentrations were approx-
mately two times higher among patients who were not
eizure free as those who were seizure free (12.5g/mL
ersus 6.3g/mL) suggests that inadequate dose was not a
eason for lack of response to lamotrigine in those patients
ho did not become seizure free by the end of the Escalation
hase.
This study extends the results of previous open-label
esearch supporting the efﬁcacy of lamotrigine for absence
eizures (Kluger et al., 2001; Duchowny et al., 2002;
rodbeck et al., 2006), as well as ﬁndings of a placebo-
ontrolled trial of lamotrigine monotherapy in newly
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iagnosed typical absence seizures in children (Frank et al.,
999). This study adds to the current literature on lamotrig-
ne in absence seizures by demonstrating that efﬁcacy was
een by the ﬁfth week off therapy. Because there is evidence
hat slow titrations of lamotrigine reduce the risk of serious
ash with lamotrigine (Messenheimer, 1998; Hirsch et al.,
006), in this study we elected to mimic clinical practice
nd used an open-label approach where the dosage esca-
ation was identical to that approved for package labeling
y the FDA. Because of this slow titration there was con-
ern that efﬁcacy would not be seen until a target dose of
—10mg/kg was reached. However, some patients started
esponding at doses as low as 1.2mg/kg.
Effective control of typical absence seizures is impor-
ant given their potential impact on children’s safety as
ell as behavior, cognition, and psychosocial function during
critical period of development. Typical absence seizures
ay affect children’s safety by increasing risk of acciden-
al injury. In a study of children and adolescents <18 years
ld diagnosed with either typical absence epilepsy or juve-
ile rheumatoid arthritis (a control group deﬁned by having
non-neurological chronic disease), the risk of acciden-
al injury, particularly mild head injuries and injuries from
icycle accidents or car accidents, was signiﬁcantly higher
n patients with typical absence epilepsy than patients
ith juvenile rheumatoid arthritis (Posner, 2005; Posner
t al., 2005a). Data from these cohorts also suggest that
bsence seizures can cause persistent deﬁcits in behav-
oral and psychosocial functioning. At a follow-up interview
onducted when patients were 23 years old on average,
hose with typical absence epilepsy had poorer function-
ng in the academic-personal and behavioral domains than
atients with juvenile rheumatoid arthritis (Frank et al.,
999; Posner, 2005, 2006; Posner et al., 2005a). Out-
omes were poorest among those with ongoing absence
eizures.
For these reasons, we set very high criteria for entrance
nto the Maintenance Phase, total seizure freedom by HV
EG maintained over 2 weeks. Because absence seizures can
e subtle and missed by parents and caregivers, to assure
hat we were achieving total seizure control we required
4 h EEGs at baseline and again following the end of the
scalation Phases in children. We anticipated that the 24 h
EG would detect seizure events not observed by parents
r detected in a 1 h EEG. Indeed, we found that the patient
iaries and EEG with hyperventilation over-estimated the
umber of children who were seizure free, when compared
o the 24 h EEG. While total seizure control was seen in less
han half of the children, based on the 24 h EEG, it should
e noted that the mean number of absence seizures per
4 h decreased from 60.4± 49.9 at baseline to 25.6± 44.5
t the end of titration. While reducing seizure frequency by
reater than 50% is certainly beneﬁcial, the goal is to obtain
otal seizure control, hence the termination of the study
n the lamotrigine non-responders. Coppola et al. (2004a,b)
lso required 100% seizure control in their cohort of children
ith typical absence seizures who received either valproate
r lamotrigine monotheraphy in open-label studies. As in
his study Coppola et al. (2004a,b) used 24 h EEG records to
onﬁrm seizure freedom although it was not clear what EEG
riteria was used to classiﬁed the electrical discharges as
eizures.
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Limitations of this study should be considered in inter-
reting the data. The study was of open-label design and did
ot include a placebo control group. The impact of these
imitations on the primary endpoint is arguably negligible
iven that absence seizures on EEG are reliably identiﬁed
nd should be subject to little if any misinterpretation.
o compensate for the lack of a placebo control group,
he seizure-free rate in the lamotrigine-treated patients in
he current sample was compared with a historical placebo
esponse rate of 20%, which was based on the observed
eizure-free rate in the placebo group in the controlled
linical trial of lamotrigine for typical absence seizures.
his seizure-free rate on placebo was observed in patients
ho converted from open-label lamotrigine to double-blind
reatment with placebo after achieving seizure-freedom
n lamotrigine monotherapy. The observed rate at which
hese patients maintained their seizure control over 4 weeks
f placebo treatment and concomitant taper of lamotrig-
ne probably overestimates the true placebo response that
ould have been observed with placebo without concomi-
ant lamotrigine. The seizure-free rate with lamotrigine in
he current study was signiﬁcantly higher than the 20% his-
orical placebo response, which would constitute a high
emission rate for newly diagnosed patients.
Lamotrigine was generally well tolerated in this study.
he pattern and incidence of adverse events were consis-
ent with those in previous studies of children and adults.
o cases of serious rash were reported. In the clinical devel-
pment program for lamotrigine, a 10% rate of non-serious
ash reported in most clinical trials, in line the ﬁndings
rom this study. Investigators were instructed to deem a
ash drug related unless a speciﬁc cause could be identi-
ed. In this study, none of the investigators considered rash
rug related. However, even with the slow titration rate
sed here it is important for the clinician to be aware of
erious dermatological responses to lamotrigine, including
tevens Johnson syndrome and toxic epidermal necrolysis
Guberman et al., 1999; Hirsch et al., 2006).
Lamotrigine therapy was associated with improvements
n the Children’s Behavior Checklist although the Children’s
lobal Assessment and Self-Perception Proﬁle for Children
id not change from baseline. Only patients who became
eizure-free at the end of dose escalation had health out-
omes measured. Since seizure frequency, duration and
ntensity improved during the course of study it is some-
hat surprising that there were no changes in the latter two
ests. While these were healthy children with newly onset
eizures, it is likely that these children were well gener-
lly adjusted at the time of entry into the study and that
ceiling effect occurred. However, the investigator rating
f patients’ status showed signiﬁcant improvements in over-
ll status, social functioning, and motor functions while in
he parents’ assessment 100% of the patients were rated as
howing moderate or marked improvement from the begin-
ing of the study to the Maintenance Phase. While these
esults must be interpreted cautiously in view of the lack
f a placebo control group, they do support the view that
amotrigine is well tolerated and has some beneﬁcial effects
n behavior, motor function, and social skills.
In conclusion, lamotrigine monotherapy was effective
nd well tolerated for the treatment of typical absence
eizures in newly diagnosed patients. Lamotrigine is an
ce s
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PLamotrigine monotherapy for newly diagnosed typical absen
important therapeutic option for managing typical absence
seizures. This study does not answer the question of which
drug is the best in regards to efﬁcacy and tolerability for typ-
ical absence seizures. Whether lamotrigine is more effective
than other antiepileptic drugs in typical absence seizures
is not clear. In the Standard and New Antiepileptic Drugs
(SANADs) trial, valproate was found to be superior to lam-
otrigine in an unblinded, randomized trial (Marson et al.,
2007). Unfortunately, there was insufﬁcient power to allow
the authors to make deﬁnite statements about the relative
efﬁcacy and effectiveness of the drugs for individual seizure
types and sub-syndromes within the idiopathic generalized
epilepsies. The answer to the question of the best drug for
typical absence seizures will have to await a large, multi-
center comparison study of lamotrigine, ethosuximide, and
valproate in absence seizures currently being conducted by
the National Institutes of Health.
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